Business Context and Reporting Period
This Form 8-K Current Report was filed by Ovid Therapeutics Inc. on June 4, 2021. The filing addresses significant changes in executive leadership, specifically the resignation of the Executive Vice President of Finance and the appointment of a new Chief Business and Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensatory arrangements.
Material Changes
- Resignation: Timothy Daly resigned as Executive Vice President, Finance, Corporate Controller, and Treasurer, effective June 22, 2021. The resignation was not due to any disagreement regarding operations, policies, or financial controls.
- Appointment: Jeffrey Rona, previously the Chief Business Officer, was appointed as Chief Business and Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective June 2, 2021.
- Compensation Adjustment: Mr. Rona's Executive Employment Agreement was amended to set an annual base salary of $455,000.
- Equity Grant: Mr. Rona was granted an option to purchase 100,000 shares of common stock with an exercise price of $4.42 per share (closing price on June 2, 2021). The option vests 25% after one year and the remainder over 36 monthly installments.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. It notes that there are no reportable related party transactions or family relationships between Mr. Rona and other officers or directors. The full text of the Amended Employment Agreement is referenced as an exhibit to be filed in the subsequent Form 10-Q.
Investor Verification Checklist
- Verify the transition timeline for financial reporting responsibilities between Timothy Daly and Jeffrey Rona.
- Review the full Amended Employment Agreement for Mr. Rona in the upcoming Form 10-Q for the period ending June 30, 2021.
- Confirm the vesting schedule and exercise terms of the 100,000 share option granted to Mr. Rona.
- Monitor future filings for the appointment of a permanent replacement for the Treasurer role if Mr. Rona does not assume it permanently.